Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: Characteristics of the responders

• Published in: European journal of cancer (1990) Vol. 48; no. 12; pp. 1799 - 1808
• Main Authors: Gök, Murat, Heideman, Daniëlle A.M, van Kemenade, Folkert J, de Vries, Anton L.M, Berkhof, Johannes, Rozendaal, Lawrence, Beliën, Jeroen A.M, Overbeek, Lucy, Babović, Milena, Snijders, Peter J.F, Meijer, Chris J.L.M
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01.08.2012; Elsevier
• Subjects: Adult; Age; Biological and medical sciences; Cancer prevention; Cervical carcinoma; Cervical intraepithelial neoplasia (CIN); Cervical Intraepithelial Neoplasia - diagnosis; Cervical Intraepithelial Neoplasia - ethnology; Cervix Uteri - virology; Ethnicity; Female; Hematology, Oncology and Palliative Medicine; Human papillomavirus; Humans; Mass Screening - methods; Medical sciences; Middle Aged; Netherlands; Non-attendees; Papillomavirus Infections - diagnosis; Papillomavirus Infections - ethnology; Pharmacology. Drug treatments; Population-based cervical screening; Screening history; Self-sampling; Specimen Handling - methods; Tumors; Vaginal Smears - methods; Netherlands; Self-sampling; Human papillomavirus; Ethnicity; Cervical intraepithelial neoplasia (CIN); Screening history; Non-attendees; Cancer prevention; Cervical carcinoma; Population-based cervical screening; Age; Samplings; Papovaviridae; Papillomavirus; Prevention; Cancerology; Cervical dysplasia; Cervical intraepithelial neoplasia; Premalignant lesion; CIN; Malignant tumor; Medical screening; Ethnic group; Female genital diseases; Infection; Virus; Viral disease; Cervix carcinoma; Uterine cervix diseases; Cervical cancer; Cancer
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/j.ejca.2011.11.022

Abstract Background Self-sampling for high-risk human papillomavirus (hrHPV) testing is accepted by up to 30% of non-attendees to the regular cervical screening programme. Here, the yield of cervical intraepithelial neoplasia (CIN)2 or worse (⩾CIN2) and CIN3 or worse (⩾CIN3) of 15, 274 HPV self-sampling responders amongst non-attendees were compared to that of 176, 027 women participating in regular screening in the same period and in the same region. We also analysed which subpopulations amongst non-attendees are targeted by HPV self-sampling, and which characteristics relate to hrHPV prevalence and yield of ⩾CIN2/⩾CIN3. Method Data from two consecutive self-sampling studies were pooled. ⩾CIN2/⩾CIN3 yields, screening history, age and ethnic status were retrieved from centralised pathology and screening databases, respectively. A logistic regression model was fitted to analyse method of invitation, ethnicity, age group, and screening history as predictors for response rate, hrHPV presence and ⩾CIN2/⩾CIN3 in non-attendees. For screening history analyses, women <34 years were excluded since it was the first screening round in their life. Findings ⩾CIN2/⩾CIN3 yields of HPV self-sampling responders were higher than those of screening participants (⩾CIN2: relative risk (RR) = 1.6, 95% confidence interval = 1.4–1.9; ⩾CIN3: RR = 1.8, 95% CI = 1.5–2.1 with relative risk values increasing with age (test of homogeneity: ⩾CIN2: p = 0.04; ⩾CIN3: p = 0.03). Native Dutch non-attendees responded better than immigrants (32% versus 22%, p < 0·001) and those screened in the previous round revealed a higher response than underscreened (i.e. previous smear taken >7 years ago) or never screened (34% versus 25%, p < 0·001) women. Strikingly, amongst under- and never screened women aged ⩾39 years, never screened women responded better (25% versus 23%, p < 0·001). ⩾CIN2 rates were higher amongst responding native Dutch women than immigrants ( p < 0·01), and higher in under-/never screened women than in women screened in the previous round ( p < 0·01). Interpretation Offering hrHPV self-sampling increases the efficacy of the screening programme by targeting a substantial portion of non-attendees of all ethnic groups who have not regularly been screened and are at highest risk of ⩾CIN2.